Hansen Medical Announces 2014 Second Quarter Results Conference Call
24 7월 2014 - 6:00AM
Hansen Medical, Inc. (Nasdaq:HNSN), a global leader in
intravascular robotics, today announced it will release its
financial and operating results for the second quarter ended June
30, 2014, after market close on Thursday, July 31, 2014.
Cary Vance, President and Chief Executive Officer, and Chris
Lowe, Interim Chief Financial Officer, will host a conference call
at 5:00 p.m. ET (2:00 p.m. PT) on July 31, 2014 to discuss the
Company's results. The call may be accessed by dialing
877-419-6603, or 719-325-4879 for international callers, and
referencing the participant code 7639526. The Company will also
provide a live webcast of the call. Interested participants may
access the webcast on the Investor Relations page of the Company's
website, http://investor-relations.hansenmedical.com/. Please go to
the website at least 15 minutes early to register, download and
install any necessary audio software.
For those unable to participate in the live broadcast, a replay
will be available two hours after the call ends through Thursday,
August 14, 2014, at 877-870-5176 or 858-384-5517 for international
callers, access code 7639526. A replay of the call will be archived
on the Investor Relations page of the Company's website.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is a
global leader in Intravascular Robotics, developing products and
technology designed to enable the accurate positioning,
manipulation and control of catheters and catheter-based
technologies. The Company's Magellan™ Robotic System, 9Fr Magellan™
Robotic Catheter, Magellan™ 6Fr Robotic Catheter, and related
accessories are intended to facilitate navigation to anatomical
targets in the peripheral vasculature and subsequently provide a
conduit for manual placement of therapeutic devices. The Magellan
9Fr Robotic Catheter has undergone both CE marking and 510(k)
clearance and is commercially available in the European Union, and
the U.S. The Magellan 6Fr Robotic Catheter has undergone 510(k)
clearance in the U.S. and is in limited release for the next
several months in anticipation of more wide-scale commercially
availability later in 2014. In the European Union, the
Company's Sensei® X Robotic Catheter System and Artisan® and
Artisan Extend® Control Catheters are cleared for use during
electrophysiology (EP) procedures, such as guiding catheters in the
treatment of atrial fibrillation (AF), and the Lynx® Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S., the
Company's Sensei X Robotic Catheter System and Artisan and Artisan
Extend Control Catheters are cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in EP procedures. In the U.S., the Sensei X Robotic
Catheter System is not approved for use in guiding ablation
procedures; this use remains experimental. The U.S. product
labeling therefore provides that the safety and effectiveness of
the Sensei X Robotic Catheter System and Artisan and Artisan Extend
Control Catheter for use with cardiac ablation catheters in the
treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
www.hansenmedical.com.
"Artisan Extend," "Hansen Medical," "Hansen Medical (with Heart
Design)," "Heart Design (Logo)," "Sensei," "Lynx," "Artisan,"
"Instinctive Motion," "Fine Force Technology," "IntelliSense" are
registered trademarks, and "Magellan" and "Hansen Medical Magellan"
are trademarks of Hansen Medical, Inc. in the U.S. and other
countries.
CONTACT: Investor Contacts:
Chris Lowe
Chief Financial Officer
Hansen Medical, Inc.
650.404.5800
Westwicke Partners, LLC.
Mark Klausner or Mike Piccinino, CFA
443.213.0501
HansenMedical@westwicke.com
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024